Skip to main content
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1975 Jan;1(1):116–117. doi: 10.1128/jcm.1.1.116-117.1975

Production of Human Lymphoblastoid Interferon

H Strander *, K E Mogensen *, K Cantell *
PMCID: PMC274964  PMID: 170301

Abstract

The interferon response of 21 lines of human lymphoblasts varied greatly. Interferon from the best producer (11,000 U/ml) resembled human leukocyte interferon.

Full text

PDF
116

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cantell K., Pyhälä L. Circulating interferon in rabbits after administration of human interferon by different routes. J Gen Virol. 1973 Jul;20(1):97–104. doi: 10.1099/0022-1317-20-1-97. [DOI] [PubMed] [Google Scholar]
  2. Edy V. G., Billiau A., Joniau M., De Somer P. Stabilisation of mouse and human interferons by acid pH against inactivation due to shaking and guanidine hydrochloride. Proc Soc Exp Biol Med. 1974 May;146(1):249–253. doi: 10.3181/00379727-146-38080. [DOI] [PubMed] [Google Scholar]
  3. Klein G., Dombos L., Gothoskar B. Sensitivity of Epstein-Barr virus (EBV) producer and non-producer human lymphoblastoid cell lines to superinfection with EB-virus. Int J Cancer. 1972 Jul 15;10(1):44–57. doi: 10.1002/ijc.2910100108. [DOI] [PubMed] [Google Scholar]
  4. Levy-Koenig R. E., Golgher R. R., Paucker K. Immunology of interferons. II. Heterospecific activities of human interferons and their neutralization by antibody. J Immunol. 1970 Apr;104(4):791–797. [PubMed] [Google Scholar]
  5. Merigan T. C., Reed S. E., Hall T. S., Tyrrell D. A. Inhibition of respiratory virus infection by locally applied interferon. Lancet. 1973 Mar 17;1(7803):563–567. doi: 10.1016/s0140-6736(73)90714-9. [DOI] [PubMed] [Google Scholar]
  6. Mogensen K. E., Cantell K. Human leukocyte interferon: a role for disulphide bonds. J Gen Virol. 1974 Jan;22(1):95–103. doi: 10.1099/0022-1317-22-1-95. [DOI] [PubMed] [Google Scholar]
  7. Mogensen K. E., Cantell K. Loss of specific antigenicity on carboxymethylation of mercaptoethanol-reduced interferon of human leukocyte origin. Intervirology. 1974;2(1):52–55. doi: 10.1159/000149405. [DOI] [PubMed] [Google Scholar]
  8. Nyormoi O., Klein G., Adams A., Dombos L. Sensitivity to EBV superinfection and IUdR inducibility of hybrid cells formed between a sensitive and a relatively resistant Burkitt lymphoma cell line. Int J Cancer. 1973 Sep 15;12(2):396–408. doi: 10.1002/ijc.2910120211. [DOI] [PubMed] [Google Scholar]
  9. Strander H., Cantell K., Carlström G., Jakobsson P. A. Clinical and laboratory investigations on man: systemic administration of potent interferon to man. J Natl Cancer Inst. 1973 Sep;51(3):733–742. doi: 10.1093/jnci/51.3.733. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES